Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
2025 · Nature Medicine · 88 citations
https://doi.org/10.1038/s41591-024-03415-7
Z
Zhenzhen Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
467
Papers
6.7K
Citations
43
h-index
168
i10-index
Zhenzhen Liu is an academic researcher from Anhui Agricultural University. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 43, co-authored 397 publications.
ORCID: 0000-0002-3878-1258Papers by this author
worksBioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics
2019 · Acta Pharmaceutica Sinica B · 66 citations
https://doi.org/10.1016/j.apsb.2019.11.001
Multi-pesticides residue analysis of grains using modified magnetic nanoparticle adsorbent for facile and efficient cleanup
2017 · Food Chemistry · 57 citations
https://doi.org/10.1016/j.foodchem.2017.03.082
An Orc1/Cdc6 ortholog functions as a key regulator in the DNA damage response in Archaea
2018 · Nucleic Acids Research · 48 citations
https://doi.org/10.1093/nar/gky487
Emergence of Extensively Drug-Resistant Proteus mirabilis Harboring a Conjugative NDM-1 Plasmid and a Novel Salmonella Genomic Island 1 Variant, SGI1-Z
2015 · Antimicrobial Agents and Chemotherapy · 48 citations
https://doi.org/10.1128/aac.00292-15
CACA Guidelines for Holistic Integrative Management of Breast Cancer
2022 · Holistic Integrative Oncology · 46 citations
https://doi.org/10.1007/s44178-022-00007-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat